Davin Devara

Davin Devara

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Davin DevaraDavin Devara
Davin Devara
YCYashmit Choudhary
Yashmit Choudhary
Subodh KumarSubodh Kumar
Subodh Kumar
MicroRNAs (miRNAs) are non-coding RNAs that play a major role in gene regulation in several diseases. MicroRNA-502-3p (MiR-502-3p) has been previously characterized in a variety of human diseases such as osteoporosis, diabetes, tuberculosis, cancers, and neurological disorders. Our studies recently explored the new role of miR-502-3p in regulating synapse function in Alzheimer’s disease (AD). AD is the most common cause of dementia in elderly individuals. Synapse is the initial target that is hit during AD progression. The most common causes of synapse dysfunction in AD are amyloid beta, hyperphosphorylated tau, and microglia activation. MiR-502-3p was found to be localized and overexpressed in the AD synapses. Overexpression of miR-502-3p was correlated with AD severity in terms of Braak stages. Studies have shown that miR-502-3p modulates the glutaminergic and GABAergic synapse function in AD. The current study’s emphasis is to discuss the in-depth roles of miR-502-3p in human diseases and AD and the future possibilities concerning miR-502-3p as a therapeutic for AD treatment.

28 June 2025 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
Subodh KumarSubodh Kumar
Subodh Kumar
Enrique RamosEnrique Ramos
Enrique Ramos
AHAxel Hidalgo
Axel Hidalgo
DRDaniela Rodarte
Daniela Rodarte
BSBhupender Sharma
Bhupender Sharma
SGShrikanth Gadad
Shrikanth Gadad
Synapse dysfunction is an early event in Alzheimer’s disease (AD) caused by various factors, including amyloid beta, p-tau, inflammation, and aging. However, the precise molecular mechanism underlying synapse dysfunction in AD remains largely unknown. To understand this, we comprehensively analyzed the synaptosomes fraction in post-mortem brain samples from AD patients and cognitively normal individuals. We conducted high-throughput transcriptomic analyses to identify changes in microRNA (miRNA) and mRNA levels in synaptosomes extracted from the brains of unaffected individuals and those with AD. Additionally, we performed mass spectrometry analysis of synaptosomal proteins in the same sample group. These analyses revealed significant differences in the levels of miRNAs, mRNAs, and proteins between the two groups. To gain further insights into the pathways or molecules involved, we employed an integrated omics approach to study the molecular interactions of deregulated synapse miRNAs, mRNAs, and proteins in samples from individuals with AD and the control group, demonstrating the impact of deregulated miRNAs on their target mRNAs and proteins. Furthermore, the DIABLO analysis revealed complex relationships among mRNAs, miRNAs, and proteins that could be key in understanding the pathophysiology of AD. Our study identified novel synapse-associated candidates that could be critical in restoring synapse dysfunction in AD.

2 February 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
JRJaime Ramirez-Gomez
Jaime Ramirez-Gomez
SDSarthak Dalal
Sarthak Dalal
Davin DevaraDavin Devara
Davin Devara
BSBhupender Sharma
Bhupender Sharma
DRDaniela Rodarte
Daniela Rodarte
Subodh KumarSubodh Kumar
Subodh Kumar
Alzheimer's disease (AD) is a chronic neurodegenerative disorder that is characterized by memory and physical impairment in aged individuals. microRNAs (miRNAs) are small, single-stranded noncoding RNAs that induce translational repression by binding to the 3’ UTR of a target mRNA. miRNAs play a crucial role in neurological activity by mediating cellular proliferation, synaptic plasticity, apoptosis and more. Ongoing research in patents and clinical trials have called attention to promising miRNAs as biomarkers and therapeutics in AD. Recent research has shown that miRNAs are aberrantly expressed in AD brain, blood, cerebrospinal fluid and serum. Attenuated miRNA expressions have diagnostic potential in AD by interacting with amyloid-β synthesis, phosphorylated tau, and neurofibrillary tangles. In this study, miRNA-29a, miRNA-125b, miRNA-34a, miRNA-146a, and miRNA-155 have shown promise as potential biomarker candidates for AD. Improving cognitive symptoms can be traced to restoring the endogenous miRNA activity by synthesizing miRNA mimics and miRNA antisense oligonucleotides. miRNA-483-5p, miRNA-188-5p, miRNA-219, miRNA135a/5p, miRNA-23/23b-3p, miRNA-124, and miRNA-455-3p are growing therapeutics for AD. However, miRNA-based therapeutics struggle outside of preclinical testing. miRNA-107, miRNA-206, miRNA-30/7, and miRNA-142-3p face bottlenecks in clinical trials due to a lack of experimental design, transparency and volunteer size. Patenting recent miRNA-based developments demonstrates the commitment in identifying a new biomarker and/or therapeutic for AD.

9 July 2025 in Clinical and Translational Medicine
Verified
Journal Article
Open access
Davin DevaraDavin Devara
Davin Devara
BSBhupender Sharma
Bhupender Sharma
GGGunjan Goyal
Gunjan Goyal
DRDaniela Rodarte
Daniela Rodarte
AKAditi Kulkarni
Aditi Kulkarni
Subodh KumarSubodh Kumar
Subodh Kumar
Introduction: Alzheimer's disease (AD) lacks a less invasive and early detectable biomarker. Here, we investigated the biomarker potential of miR‐501‐3p and miR‐502‐3p using different AD sources.Methods: MiR‐501‐3p and miR‐502‐3p expressions were evaluated in AD cerebrospinal fluid (CSF) exosomes, serum exosomes, familial and sporadic AD fibroblasts and B‐lymphocytes by qRT‐PCR analysis. Further, miR‐501‐3p and miR‐502‐3p expressions were analysed in APP, Tau plasmid transfected cells media exosomes and in different brain cell types.Results: MiR‐501‐3p and miR‐502‐3p expressions were significantly up‐regulated in AD CSF exosomes relative to controls. MiRNA levels were high in accordance with amyloid plaque and NFT density in multiple brain regions. Similarly, both miRNAs were elevated in AD and MCI serum exosomes compared with controls. MiR‐502‐3p expression was high in familial AD and sporadic AD B‐lymphocytes. MiR‐501‐3p and miR‐502‐3p expression were elevated intracellularly and secreted extracellularly in response to APP and Tau pathology. Finally, neurons and astrocytes displayed high expression of these miRNAs.Discussion: These results suggest that miR‐501‐3p and miR‐502‐3p could be promising biomarkers for AD.Key points: MiR‐501‐3p and miR‐502‐3p expression is elevated in AD CSF exosomes, AD serum exosomes, AD B‐lymphocytes and Aβ‐ and Tau‐treated cells. MiR‐501‐3p and miR‐502‐3p are correlated with amyloid plaque and NFT tangle density in specific brain regions. MiR‐501‐3p and miR‐502‐3p are highly expressed in neurons and astrocytes, suggesting that these cells are the source of miRNA secretion. MiR‐501‐3p and miR‐502‐3p could be a promising biomarker panel for AD

5 October 2025 in NeuroImage
Verified
Journal Article
Open access
LMLayth S. Mattar
Layth S. Mattar
SSShraddha Shah
Shraddha Shah
LCLily S. Chamakura
Lily S. Chamakura
DODenise Oswalt
Denise Oswalt
YZYue Zhang
Yue Zhang
EBEleonora Bartoli
Eleonora Bartoli
The ability to override prepotent actions is critical to control impulses and adjust behavior depending on goals and contextual needs. In this study, we investigate the inhibitory control abilities of a patient diagnosed with Klüver-Bucy Syndrome following a left temporal resection. The patient presented with disruptive hypersexuality symptoms akin to compulsions, leading to the inability to control and suppress inappropriate actions. The patient was recruited for the current research study while undergoing intracranial monitoring for epilepsy, to investigate the cognitive and neural processes underlying the patient's inhibitory control symptoms. We formulated the hypothesis that a reactive inhibitory control deficit emerges in response to provocative triggers, and we designed a personalized paradigm pairing arousing images with a classic inhibitory control task. We not only confirmed disrupted performance following exposure to triggering, provocative material, but we also leveraged the simultaneously recorded neural data to identify a biomarker reflecting inhibitory control failures. Next, we repeated the experimental paradigm during and after personalized neuromodulation via direct high-frequency stimulation of the right inferior frontal cortex. The patient displayed a marked improvement in his behavior during neuromodulation, mirrored by changes in neural activity, spanning spectral features, event-related potentials and functional connectivity. Altogether, our study revealed that the patient's symptoms were not due to a global inhibition deficit, but to a specific control issue triggered by exposure to provocative material. Overall, our work showcases a feasible, effective approach towards data-driven personalized neuromodulation, which could be leveraged to mitigate specific inhibitory control deficits and potentially other symptoms of executive dysfunction.

11 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LMLayth S. Mattar
Layth S. Mattar
SSShraddha Shah
Shraddha Shah
LCLily S. Chamakura
Lily S. Chamakura
DODenise Oswalt
Denise Oswalt
YZYue Zhang
Yue Zhang
EBEleonora Bartoli
Eleonora Bartoli
The ability to override prepotent actions is critical to control impulses and adjust behavior depending on goals and contextual needs. In this study, we investigate the inhibitory control abilities of a patient diagnosed with Klüver-Bucy Syndrome following a left temporal resection. The patient presented with disruptive hypersexuality symptoms akin to compulsions, leading to the inability to control and suppress inappropriate actions. The patient was recruited for the current research study while undergoing intracranial monitoring for epilepsy, to investigate the cognitive and neural processes underlying the patient’s inhibitory control symptoms. We formulated the hypothesis that an inhibitory control deficit emerges in response to provocative triggers, and we designed a personalized paradigm pairing arousing images with a classic inhibitory control task. We not only confirmed disrupted performance following exposure to triggering, provocative material, but we also leveraged the simultaneously recorded neural data to identify a biomarker reflecting inhibitory control failures. Next, we repeated the experimental paradigm during and after personalized neuromodulation via direct high-frequency stimulation of the right inferior frontal cortex. The patient displayed a marked improvement in his behavior during neuromodulation, mirrored by changes in neural activity, spanning spectral features, event-related potentials and functional connectivity. Altogether, our study revealed that the patient’s symptoms were not due to a global inhibition deficit, but to a specific control issue triggered by exposure to provocative material. Overall, our work showcases a feasible, effective approach towards data-driven personalized neuromodulation, which could be leveraged to mitigate specific inhibitory control deficits and potentially other symptoms of executive dysfunction. Abstract Figure: Graphical abstract. This case study investigates context-dependent inhibitory control abilities in a patient with Kluver-Bucy syndrome during intracranial monitoring for epilepsy .